• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Cheng Yin Pan

    3/24/26 10:30:07 AM ET
    $PRE
    Blank Checks
    Finance
    Get the next $PRE alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Cheng Yin Pan

    (Last)(First)(Middle)
    UNIT 703-706, K11 ATELIER
    728 KINGS ROAD, QUARRY BAY

    (Street)
    HONG KONG

    (City)(State)(Zip)

    HONG KONG

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/24/2026
    3. Issuer Name and Ticker or Trading Symbol
    Prenetics Global Ltd [ PRE ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    XForm filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Class A Ordinary Share, par value $0.0015 per share75,021IBy M13 Capital Management Holdings Limited(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Restricted Stock Unit (2)05/18/2032Class A Ordinary Share, par value $0.0015 per share15,873$0IBy M13 Capital Management Holdings Limited
    1. Name and Address of Reporting Person*
    Cheng Yin Pan

    (Last)(First)(Middle)
    UNIT 703-706, K11 ATELIER
    728 KINGS ROAD, QUARRY BAY

    (Street)
    HONG KONG

    (City)(State)(Zip)

    HONG KONG

    (Country)

    Relationship of Reporting Person(s) to Issuer
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    M13 Capital Management Holdings Ltd

    (Last)(First)(Middle)
    PORTCULLIS CHAMBERS, ELLEN SKELTON BLDG
    3076 SIR FRANCIS DRAKE HIGHWAY

    (Street)
    ROAD TOWN, TORTOLA, VG1110

    (City)(State)(Zip)

    VIRGIN ISLANDS, BRITISH

    (Country)

    Relationship of Reporting Person(s) to Issuer
    Director10% Owner
    Officer (give title below)XOther (specify below)
    Wholly owned by Cheng Yin Pan
    Explanation of Responses:
    1. M13 Capital Management Holdings Limited is a British Virgin Islands company wholly owned by Cheng Yin Pan.
    2. Each of the 15,873 Restricted Stock Units ("RSUs"), granted under the Issuer's 2022 Share Incentive Plan, represents the contingent right to receive one Class A Ordinary Share. The RSUs vest in accordance with the following schedule, subject to continued service: May 17, 2026: 15,873 (15,873 Class A Ordinary Shares). M13 Capital Management Holdings Limited's vested RSUs are not automatically settled upon vesting. Settlement and delivery of Class A Ordinary Shares in respect of vested RSUs occurs at Cheng Yin Pan's election, in accordance with the Issuer's insider trading policy.
    Remarks:
    Exhibit 24 - Powers of Attorney
    /s/ Stephen Hoi Chun Lo, as attorney-in-fact for Cheng Yin Pan03/24/2026
    /s/ Stephen Hoi Chun Lo, as attorney-in-fact for M13 Capital Management Holdings Limited03/24/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $PRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRE

    DatePrice TargetRatingAnalyst
    3/16/2026$29.00Buy
    Lake Street
    2/11/2026$36.00Buy
    Roth Capital
    1/18/2023$7.00Overweight
    Cantor Fitzgerald
    7/12/2022Buy
    Citigroup
    More analyst ratings

    $PRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Prenetics Group Ltd. with a new price target

    Lake Street initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $29.00

    3/16/26 8:45:09 AM ET
    $PRE
    Blank Checks
    Finance

    Roth Capital initiated coverage on Prenetics Group Ltd. with a new price target

    Roth Capital initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $36.00

    2/11/26 7:52:37 AM ET
    $PRE
    Blank Checks
    Finance

    Cantor Fitzgerald initiated coverage on Prenetics Group Ltd. with a new price target

    Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00

    1/18/23 7:56:45 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prenetics' IM8 Partners with Superpower to Personalize the Future of Supplementation

    IM8 90-Day Subscribers Unlock SuperPower Blood Testing for $49 — A 75% Saving on the Standard $199 Price.IM8 and Superpower create the first closed-loop system in consumer health – connecting clinical-grade supplementation with 100+ biomarker blood testing.IM8's Daily Ultimate Essentials will be available in the Superpower supplement marketplace and featured, where biomarker data supports it, as one of Superpower's recommended foundational daily supplements in members' personalized health protocols. NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium heal

    3/24/26 11:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics to Participate in the 38th Annual ROTH Conference

    NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced the Company will participate in the 38th Annual ROTH Conference being held Sunday, March 22nd to Tuesday, March 24th at the Ritz-Carlton in Laguna Niguel, CA. Prenetics CEO Danny Yeung and President of Americas David Vanderveen will be available for one-on-one meetings throughout the conference. Management will also participate in a fireside chat at 8:30 a.m. PT and a Consumer Influencer panel discussion at 12:00 p.m. PT on Monday, March 23rd — both available via webc

    3/18/26 8:30:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Authorizes $40 Million Share Repurchase Program

    Management and Board Have Collectively Committed Up to $42.75 Million to Prenetics Stock Backed by $164 Million in Total Adjusted Liquidity, Zero Debt IM8 Targeting $180M to $200M in 2026 Full Year Revenue, and a Clear Path to Adjusted EBITDA Profitability by Q4 2027 NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced that its Board of Directors (the "Board") has authorized a share repurchase program of up to $40,000,000 over a 12-month period. Management Voted With Its Own Capital First During the week of Feb

    3/6/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    SEC Filings

    View All

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    3/6/26 8:07:42 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    3/3/26 8:47:27 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    2/18/26 9:28:49 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Cheng Yin Pan

    3 - Prenetics Global Ltd (0001876431) (Issuer)

    3/24/26 10:30:07 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Lo Hoi Chun

    3 - Prenetics Global Ltd (0001876431) (Issuer)

    3/18/26 11:17:48 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 3 filed by Prenetics Global Limited

    3 - Prenetics Global Ltd (0001876431) (Issuer)

    3/18/26 11:02:27 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Financials

    Live finance-specific insights

    View All

    Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY

    Total Revenue Increased 480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 millionIM8 Reaches $10 Million in Monthly Revenue in December 2025, Achieving $120M ARR MilestoneStrategic Transformation Completed with Divestitures and Focus on IM8 Total Adjusted Liquidity2 of Approximately $171 Million Following Sale of Insighta Stake to Tencent, with Zero DebtCompany to Host Earnings Call on February 18, 2026, at 10:00 a.m. ET and latest investor deck can be found at https://ir.prenetics.com NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium he

    2/18/26 9:11:26 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics to Report Q4 and Full Year 2025 Financial Results on Feb 18, 2026 and Host Earnings Conference Call

    NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced it will release financial results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Wednesday, February 18, 2026. The Company will also hold its earnings conference call the same day at 10:00 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Wednesday, February 18, 2026Time:10:00 a.m. Eastern TimeDial-in:1-877-425-9470International Dial-in:1-201-389-0878

    2/11/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History

    Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLOTTE, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced third quarter 2025 financial

    11/10/25 7:24:27 AM ET
    $EXOD
    $PRE
    Finance: Consumer Services
    Finance
    Blank Checks

    $PRE
    Leadership Updates

    Live Leadership Updates

    View All

    Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder

    Ollie Bearman becomes the latest elite athlete to invest in NASDAQ:PRE, underscoring a deep belief in the brand's mission and products.IM8, co-founded by David Beckham, continues to attract top-tier athletes who prioritize scientifically validated and trusted nutritional support.IM8 has become one of the fastest-growing supplement brands globally, achieving an extraordinary US$100 million in Annual Recurring Revenue in just 11 months from launch.Bearman's rapid rise – including a historic points-scoring Ferrari debut at just 18—cements his reputation as one of motorsport's brightest young talents. NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading

    2/13/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to Board

    -  Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation -  Following strategic divestiture, Prenetics leverages strengthened $117M balance sheet to execute comprehensive Bitcoin strategy with board-approved majority allocation, institutional financing partnerships, and alpha-generating initiatives. CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading health sciences company, today announced it has become the first healthcare company to establish a Bitcoin treasury, completing a $20 million Bitcoin purchase of 187.42 BTC at an averag

    6/18/25 8:45:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors

    LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

    7/1/24 8:30:00 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Prenetics Global Limited

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    11/14/24 12:30:15 PM ET
    $PRE
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    2/5/24 6:05:14 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    11/27/23 6:05:43 AM ET
    $PRE
    Blank Checks
    Finance